

Contents

Foreword	<i>Stuart B. Levy</i>	xxi
Foreword to the First Edition, Revised	<i>Jacques F. Acar</i>	xxiii
Foreword to the First Edition	<i>Michel Glauser and Philippe Moreillon</i>	xxv
Preface		xxvii
Contributors		xxix

1 Historical Review of Antibacterial Chemotherapy / 1

A. BRYSKIER

1. Introduction 1
2. The Penicillin Era 5
3. The Postpenicillin Era 11

2 Antibiotics and Antibacterial Agents: Classifications and Structure-Activity Relationship / 13

A. BRYSKIER

1. Introduction 13
2. The β -Lactam Family 13
3. Aminoglycosides 16
4. Macrolides 21
5. Fluoroquinolones 24
6. Peptide Antibiotics 28
7. Ansamycins 29
8. Tetracyclines 29
9. Lincosamides 33
10. Chloramphenicol 33
11. Benzylpyrimidines 34
12. Sulfonamides 36
13. 5-Nitroimidazoles 37

3 Epidemiology of Resistance to Antibacterial Agents / 39

A. BRYSKIER

1. Introduction 39
2. Process of Bacterial Selection 39
3. In Vitro Methodology 40
4. Adaptation of Bacteria to Aggression by Antibacterial Agents 40
5. Biological Costs for Resistant Bacteria 40
6. Lower RTIs in the Community 40
7. Frequency of Nosocomial Infections 41
8. Gram-Positive Cocci 42
9. Gram-Negative Cocci 60
10. *Enterobacteriaceae* 63
11. Nonfermentative Gram-Negative Bacilli 76
12. Fastidious Gram-Negative Bacilli 80
13. Other Gram-Negative Bacilli 82
14. Anaerobic Bacteria 83
15. *Mycobacterium tuberculosis* 85
16. *Ureaplasma urealyticum* 86
17. *Chlamydia* spp. 87
18. How To Establish an Epidemiological Survey 87
19. Combating Resistance 88

4 Development of an Antibiotic: Microbiology / 93

A. BRYSKIER

1. Introduction 93
2. Preselection of a Molecule 93
3. Basic Documentation 94
4. "Core" Dossier 97
5. Animal Models 105
6. Specific Indications 105
7. Mechanisms of Action and Resistance 105
8. Interaction with Fecal and Oral Floras 106
9. Clinical Microbiology and Phases I and II: Dose Determination 106
10. Place of Clinical Microbiology in Phase II and III Clinical Studies 107
11. Epidemiological Studies 109
12. Additional Studies 109
13. Breakpoint Determinations 110
14. Conclusion 110

5 Penicillins / 113

A. BRYSKIER

1. Introduction 113
2. Classification of Penicillins 113
3. Mechanism of Action of Penicillins 113
4. Resistance Mechanisms 113
5. Group I: Penicillin G and Derivatives 113
6. Group II: Group M Penicillins 121
7. Group III: Group A Penicillins 129
8. Group IV: α -Carboxy- and α -Sulfopenicillins 148
9. Group V: 6- α -Penicillins 153
10. Group VI: Amidinopenicillins 156
11. Group VII: Oxyiminopenicillins 158

6 Cephems for Parenteral Use / 163

A. BRYSKIER AND J. ASZODI

1. Introduction 163
2. Classifications of Cephems 164

7 Oral Cephalosporins / 222

A. BRYSKIER AND M. LEBEL

1. Introduction 222
2. Classification 222
3. Physicochemical Properties 223
4. Structure-Activity Relationship 224
5. Antibacterial Activity 225
6. Epidemiology of Resistance 232
7. Pharmacokinetics 237
8. Pharmacokinetics in Specific Populations 239
9. Renal Insufficiency 247
10. Hepatic Insufficiency 248
11. Gastrectomized Patients 248
12. Metabolism 250
13. Oral Cephems under Investigation 253
14. Interactions with Other Medicinal Products 255
15. Clinical Indications 255
16. Adverse Effects 255

8 Carbapenems / 269

A. BRYSKIER

1. Background 269
2. Classification 269

3. Synthetic Molecules	271	
4. Structure-Activity Relationships	273	
5. New Derivatives	279	
6. In Vitro Antibacterial Activity	289	
7. Mechanisms of Action	292	
8. Mechanisms of Resistance	293	
9. Physicochemical Properties	295	
10. Assay Methods	296	
11. Pharmacokinetics	296	
12. Pharmacokinetics in Specific Populations	298	
13. Pharmacokinetics of Carbapenems in Pediatric Patients	299	
14. Pharmacokinetics in Patients with Renal Insufficiency	299	
15. Tissue Distribution	301	
16. Tolerance of Carbapenems	302	
17. Indications for Carbapenems	306	
18. Oral Carbapenems	308	
9 Penems / 319		
A. BRYSKIER		
1. Introduction	319	
2. Classifications	319	
3. Physicochemical Properties	319	
4. Structure-Activity Relationship	319	
5. Neurologic and Renal Tolerance	324	
6. Antibacterial Activity	326	
7. Pharmacokinetics	330	
10 Monocyclic β-Lactams / 336		
P. LE NOC		
1. Introduction	336	
2. Classification	336	
3. Structure-Activity Relationships	337	
4. Physicochemical Properties	339	
5. In Vitro Antibacterial Properties	339	
6. Mechanisms of Action	341	
7. Stability of Monocyclic β -Lactams against β -Lactamases	341	
8. Inhibition of β -Lactamases	342	
9. Induction of β -Lactamases	342	
10. Interference by Monocyclic β -Lactams with Host Defense Systems	342	
11. Pharmacokinetics of Monocyclic β -Lactams	343	
12. Tissue Distribution	344	
13. Drug Interactions	345	
14. Tolerance	345	
15. Clinical Indications	346	
11 β-Lactam Prodrugs / 348		
A. BRYSKIER		
1. Definition of a Prodrug	348	
2. Intestinal Absorption	352	
3. Absorption of β -Lactams	353	
4. Penicillin Prodrugs	356	
5. Cephalosporins	362	
6. Penems	365	
7. Carbapenem	366	
8. Metabolism	368	
12 Peptidoglycan Synthesis Inhibitors / 377		
A. BRYSKIER AND C. DINI		
1. Introduction	377	
2. Peptidoglycan	377	

3. Peptidoglycan Biosynthesis Inhibitors 381
4. Mersacidin 397

13 β -Lactamase Inhibitors / 401

A. KAZMIERCZAK

1. Introduction 401
2. β -Lactamases and Hydrolysis Reactions 401
3. β -Lactamases and Inhibition Reactions 402
4. In Vitro Activity of β -Lactamase Inhibitors 404
5. Pharmacokinetics of Inhibitors 406
6. Conclusion 409

14 β -Lactamase Inhibitors under Research / 410

ANDRÉ BRYSKIER, CATHERINE COUTURIER, AND JOHN LOWTHER

1. Introduction 410
2. Role of β -Lactamases 411
3. Rationale for Research on β -Lactamase Inhibitors 411
4. Classifications of β -Lactamases and Related Inhibitors 411
5. β -Lactamase Inhibitors 413
6. Non- β -Lactams as β -Lactamase Inhibitors 435
7. Conclusion 444

15 γ -Lactams and Derivatives / 447

A. BRYSKIER

1. Introduction 447
2. γ -Lactams 447
3. Pyrazolidinones 448
4. Lacticins 449

16 Aminocyclitol Aminoglycosides / 453

P. VEYSSIER AND A. BRYSKIER

1. Introduction 453
2. Chemical Structure and Classification 453
3. Physicochemical Properties 455
4. Antibacterial Spectrum and Activity 456
5. Mode of Action of Aminoglycosides 457
6. Structure-Activity Relationship of Aminoglycosides 458
7. Mechanisms of Bacterial Resistance to Aminoglycosides 458
8. Pharmacology of Aminoglycosides 460
9. Pharmacology in Humans 460
10. Metabolism and Excretion 460
11. Renal Behavior of Aminoglycosides and Its Effects 461
12. Distribution in Body Tissues and Fluids 461
13. Pharmacokinetics as a Function of Diathesis 462
14. Drug Interactions—Physicochemical Incompatibilities 463
15. Incidents and Accidents Associated with Aminoglycosides 464
16. Dosage and Route of Administration 468
17. Current Clinical Indications of Aminoglycosides 468
18. Conclusion 469

17 Spectinomycin / 470

A. BRYSKIER

1. Structure and Structure-Activity of Spectinomycin 470
2. Physicochemical Properties 471
3. Antibacterial Activity 471
4. Mechanisms of Action and Resistance 472
5. Epidemiology of Resistance of *N. gonorrhoeae* 472
6. Breakpoints 473

- 7. Pharmacokinetics 473
- 6. Acnrimycin 474

18 Macrolides / 475

A. BRYSKIER AND E. BERGOGNE-BÉRÉZIN

- 1. Definition of Macrolides 475
- 2. Classifications 475
- 3. Erythromycin A 475
- 4. Structure-Activity Relationships 480
- 5. Physicochemical Properties 483
- 6. Intracellular Accumulation of Macrolides 484
- 7. In Vitro Activity of Macrolides 484
- 8. Mechanism(s) of Action of Macrolides 492
- 9. Epidemiology of Resistance to Erythromycin A 495
- 10. Resistance Mechanisms 496
- 11. Plasma Pharmacokinetics of Macrolides 503
- 12. Pharmacokinetics at Different Stages of Life 507
- 13. Pharmacokinetics in Pathological Predispositions 512
- 14. Rectal Pharmacokinetics 516
- 15. Metabolism 516
- 16. Tissue Distribution 517
- 17. Pharmacodynamics 517
- 18. Drug Interactions 517
- 19. Other Effects of Macrolides 521
- 20. Therapeutic Indications 524

19 Ketolides / 527

A. BRYSKIER

- 1. Introduction 527
- 2. Epidemiology of Resistance to Macrolides 528
- 3. Classification 528
- 4. Ketolides 528
- 5. Telithromycin (HMR 3647) 536
- 6. Mechanisms of Action 540
- 7. Mechanism of Resistance of Ketolides 542
- 8. Pharmacodynamics 545
- 9. Intracellular Concentrations 546
- 10. Pharmacokinetics of Telithromycin 546
- 11. Cethromycin (ABT 773) 550
- 12. HMR 3004 551
- 13. TE-810 552
- 14. TE-802 552
- 15. 11,12-Carbamate, 6-Arylalkyl Macrolides 553
- 16. 2-Fluoroketolides 553
- 17. Other Ketolide Derivatives 557

20 Streptogramins / 570

A. BRYSKIER

- 1. Introduction 570
- 2. Classifications and Physicochemical Properties of Natural Streptogramins 570
- 3. Pristinamycins 573
- 4. Dalfopristin-Quinupristin (RP-59500) 581
- 5. RPR 106972 587
- 6. XRP 2868 590

21 Lincosamines / 592

A. BRYSKIER

1. Introduction 592
2. Pharmacokinetics 597
3. Therapeutic Indication 602

22 Oxazolidinones / 604

A. BRYSKIER

1. Introduction 604
2. Chemical Structures 605
3. Structure-Activity Relationship 606
4. Physicochemical Properties 608
5. DuP 105 and DuP 721 608
6. Linezolid and Eperezolid 611
7. AZD 2563 614
8. Ranbezolid 615
9. Mechanisms of Action and Resistance 616
10. New Investigational Molecules 616

23 Fusidic Acid / 631

A. BRYSKIER

1. Introduction 631
2. Classifications 631
3. Production 631
4. Structure and Physicochemical Properties 631
5. Structure-Activity Relationship 632
6. Toxicological and Pharmacological Properties 635
7. Antibacterial Properties 635
8. Mechanisms of Action 636
9. Resistance Mechanisms 638
10. Antibiotic Combinations 639
11. PAE 639
12. Antiparasitic Activity 639
13. Plasma Pharmacokinetics 639
14. Tissue Distribution 640
15. Eyedrops 640
16. Other Properties 640
17. Clinical Indications 641

24 Tetracyclines / 642

A. BRYSKIER

1. Introduction 642
2. Chemical Structures 642
3. Classification 642
4. Physicochemical Properties 642
5. In Vitro Properties 643
6. Mechanisms of Action 644
7. Resistance Mechanisms 646
8. Pharmacokinetics 649
9. Tissue Distribution 649
10. Drug Interactions 649
11. Safety 650
12. Clinical Indications 650

25 Tetracyclines under Investigation / 652

A. BRYSKIER

1. Introduction 652
2. Classification of Cyclines 652
3. Tetracycline Resistance Mechanisms 652

4. Structural Modifications of Tetracyclines	654
5. Bactericidal Cyclines	654
6. Dactylocyclines	656
7. Glycylcyclines	656
8. 8-Methoxychlortetracycline Derivatives	663
9. PTK 0796 (BAY 73-6944)	664
10. Other Tetracyclines	664
26 Fluoroquinolones / 668	
A. BRYSKIER	
1. Introduction	668
2. Chemical Structures	669
3. Structure-Activity Relationship	670
4. Classifications	677
5. Antibacterial Activity of Fluoroquinolones	682
6. Mechanisms of Action of Fluoroquinolones	714
7. Resistance Mechanisms of Fluoroquinolones	727
8. Pharmacodynamics	736
9. Pharmacokinetics	737
10. Tissue Distribution	748
11. Interactions	757
12. Clinical Indications	765
13. Safety	781
27 DNA Gyrase Inhibitors Other Than Fluoroquinolones / 789	
A. BRYSKIER	
1. Introduction	789
2. Cinodines	789
3. Coumamidine	790
4. Pyrimido[1,6- <i>a</i>]Benzimidazoles	790
5. Cyclothialidine (Ro-09-1437)	791
6. Clerocidin	792
7. 2-Pyridone Carboxylic Acid Derivatives	792
8. CJ-12371 and CJ-12372	793
9. Microcin B17	794
28 Codrugs / 798	
A. BRYSKIER	
1. Introduction	798
2. Rationale of Codrugs	798
3. Definition	799
4. Classification	799
5. Mechanisms of Action	800
6. Mechanisms of Resistance	803
7. Physicochemical Properties	804
8. Cephalosporin-Type Derivatives	804
9. Penem-Quinolone Combinations	809
10. Carbapenems-Fluoroquinolones	812
11. Penicillins-Quinolones	813
12. Monocyclic β -Lactams/Quinolones	813
13. Oxazolidinones-Quinolones	814
29 Coumarin Antibiotics: Novobiocin, Coumermycin, and Clorobiocin / 816	
A. BRYSKIER AND M. KLICH	
1. Introduction	816
2. Structure and Physicochemical Properties	816
3. Structure-Activity Relationship	820

- 4. In Vitro Antibacterial Activity 820
- 5. Novobiocin: Laboratory Tests 821
- 6. Mechanism of Action 822
- 7. Toxicology 824
- 8. Pharmacokinetics 824

30 Peptide Antibiotics / 826

A. BRYSKIER

- 1. Introduction 826
- 2. Antibiotics of Miscellaneous Origin 826
- 3. Lantibiotics 831
- 4. Group I: Linear Peptides 833
- 5. Group II: Cyclic Peptides 839
- 6. Group III: Glycopeptides 843
- 7. Group IV: Lipoglycopeptides 848
- 8. Group V: Lipopeptides 854
- 9. Group VI: Thiazolopeptides 870
- 10. Group VII: Thiopeptides and Chromopeptides 874
- 11. Miscellaneous Peptides 875

31 Glycopeptides and Lipoglycopeptides / 880

A. BRYSKIER

- 1. Introduction 880
- 2. Classification 880
- 3. Vancomycin 881
- 4. Teicoplanin 885
- 5. Oritavancin 895
- 6. Dalbavancin 896
- 7. AC 98-6646 898
- 8. Televancin 900

32 Ansamycins / 906

A. BRYSKIER

- 1. Introduction 906
- 2. Classification 906
- 3. Chemical Structure 907
- 4. Structure-Activity Relationship 907
- 5. Physicochemical Properties of Rifamycins 910
- 6. Production of Rifamycins 911
- 7. Assays of Rifampin 911
- 8. Stability of Ansamycins in Culture Media 911
- 9. Mechanisms of Action 911
- 10. Resistance 912
- 11. In Vitro Activity 914
- 12. Plasma Pharmacokinetics 914
- 13. Therapeutic Indications 921
- 14. Drug Interactions 923
- 15. Adverse Effects 923

33 Phenicol / 925

A. FISCH AND A. BRYSKIER

- 1. Introduction 925
- 2. Chemical Structures and Physicochemical Properties 925
- 3. In Vitro Properties 926
- 4. Mechanism of Action 927
- 5. Mechanisms of Resistance 927
- 6. Plasma Pharmacokinetics 927
- 7. Tissue Distribution 928
- 8. Drug Interference 928

- 9. Tolerance 928
- 10. Clinical Indications 929

34 5-Nitroimidazoles / 930

L. DUBREUIL

- 1. Introduction 930
- 2. Structure 930
- 3. Physicochemical Properties 930
- 4. Antibacterial Activity 930
- 5. Pharmacokinetics of Metronidazole 934
- 6. Pharmacokinetics of Ornidazole 937
- 7. Pharmacokinetics of Tinidazole 938
- 8. Adverse Effects of the 5-Nitroimidazoles 938
- 9. Changes in Biochemical Constants 938
- 10. Drug Interactions 938
- 11. Therapeutic Indications 938
- 12. Physicochemical Incompatibilities 939
- 13. Dosage 939
- 14. Conclusion 940

35 Dihydrofolate Reductase Inhibitors, Nitroheterocycles (Furans), and 8-Hydroxyquinolines / 941

P. VEYSSIER AND A. BRYSKIER

- 1. Sulfonamides and Combinations 941
- 2. New Exploratory Derivatives 956
- 3. Sulfones 957
- 4. Nitroheterocycles: Furans 960
- 5. 8-Hydroxyquinoline Derivatives 961

36 Mupirocin / 964

A. BRYSKIER

- 1. Introduction 964
- 2. Structure of Pseudomonic Acid 964
- 3. Physicochemical Properties 964
- 4. Antibacterial Properties 964
- 5. Pharmacokinetics and Metabolism 967
- 6. Semisynthetic Derivatives 968
- 7. Therapeutic Activity 969

37 Fosfomicin and Derivatives / 972

E. BERGOGNE-BÉRÉZIN

- 1. Introduction 972
- 2. Chemical Structure 972
- 3. Classification 972
- 4. Physicochemical Properties 972
- 5. In Vitro Properties 973
- 6. Mechanisms of Action of Fosfomicin 976
- 7. Mechanisms of Resistance 976
- 8. Plasma Pharmacokinetics 977
- 9. Tissue Distribution 979
- 10. Drug Interference 980
- 11. Tolerance 980
- 12. Clinical Indications 981

38 Orthosomycins / 983

A. BRYSKIER

- 1. Summary 983
- 2. Background 983
- 3. Classification 983

4. Physicochemical Properties of Evernimicin 986
5. Structure-Activity Relationship 987
6. Antibacterial Activity of Evernimicin 987
7. Mechanism of Action 988
8. Mechanisms of Resistance 988
9. Pharmacodynamics 989
10. Pharmacokinetics 989
11. Clinical Indications 990
12. Conclusion 990

39 Peptidyl Deformylase Inhibitors / 991

ANDRÉ BRYSKIER AND JOHN LOWTHER

1. Introduction 991
2. PDF 991
3. Deformylase inhibitors 995

40 *Helicobacter pylori* and Antibacterial Agents / 1011

ANDRÉ BRYSKIER, JOHN LOWTHER, AND CATHERINE COUTURIER

1. Introduction 1011
2. *H. pylori*: Taxonomy 1011
3. Epidemiology of *H. pylori* Infection 1012
4. Virulence of *H. pylori* 1012
5. Treatment of *H. pylori* Infections 1013
6. In Vitro Studies 1014
7. Animal Studies 1015
8. Epidemiology of Resistance to *H. pylori* 1015
9. Nonantibacterial Agents 1021
10. Antibacterial Agents 1026
11. Miscellaneous Anti-*H. pylori* Agents 1044

41 Microbial Efflux of Antibiotics and Inhibitors of Efflux Pumps / 1055

ANDRÉ BRYSKIER

1. Introduction 1055
2. Role of Efflux Pumps 1055
3. Potential Role in Antibacterial Resistance 1055
4. Classification of Efflux Pumps 1056
5. MFS Family 1057
6. SMR Family 1063
7. MATE Family 1064
8. RND Family 1066
9. ABC Transporters 1072
10. Antibacterials and Efflux 1073
11. Magnitude of Resistance to Efflux Pumps 1075
12. Efflux Pump Inhibitors 1075

42 Paldimycin / 1085

A. BRYSKIER

1. Introduction 1085
2. Structure of the Paulomycins 1085
3. Physicochemical Properties 1085
4. In Vitro Activity 1085

43 Antituberculosis Agents / 1088

ANDRÉ BRYSKIER AND JACQUES GROSSET

1. Introduction and History of TB 1088
2. In Vitro Testing of Anti-TB Drugs 1092
3. Anti-TB Antibiotics 1092
4. Streptomycin 1092

5.	Ansamycin Derivatives	1093	
6.	Derivatives of Rifamycin SV	1095	
7.	Isoniazid	1099	
8.	Pyrazinamide	1102	
9.	Ethambutol	1103	
10.	Thioamides: Ethionamide and Prothionamide		1104
11.	PAS	1105	
12.	D-Cycloserine	1106	
13.	Viomycin	1108	
14.	Capreomycin	1108	
15.	Thiacetazone	1108	
16.	Tioacarlide (Isoxyl)	1109	
17.	Other drugs	1109	
18.	Resistance of Tubercle Bacilli to Antibacterials		1111
19.	Mechanisms of Resistance of TB	1118	
20.	Rational Bases of Anti-TB Treatment	1119	
21.	Preventing Selection of Resistant Mutants	1120	
22.	Sterilizing Lesions	1120	
23.	Chemotherapy of TB: Recommended Antibiotic Combinations		1121
24.	Latent TB	1121	
44	Fluoroquinolones and Tuberculosis: a Review	/	1124
ANDRÉ BRYSKIER AND JOHN LOWTHER			
1.	Introduction	1124	
2.	Rationale for Using Fluoroquinolones	1124	
3.	In Vitro Activity of Fluoroquinolones	1125	
4.	Mechanism of Resistance	1131	
5.	Animal Experimental TB	1134	
6.	Structure-Activity Relationships	1135	
7.	New Quinolones with Antimycobacterial Activity		1137
8.	Clinical Studies	1137	
9.	Role of Fluoroquinolones in TB	1140	
10.	Fluoroquinolones as a Diagnostic Test	1141	
11.	Conclusion	1141	
45	Antituberculosis Compounds under Investigation	/	1146
A. BRYSKIER			
1.	Introduction	1146	
2.	"Ideal" Profile for New Anti-TB Agents	1146	
3.	Early Investigations for New Potential Anti-TB Agents		1146
4.	Alterations of Existing Compounds	1147	
5.	Alterations of Existing Antibacterial Agents	1152	
6.	New Targets and Compounds	1154	
7.	Natural Compounds	1157	
8.	Other Derivatives	1160	
46	Antibacterial Treatment of Leprosy	/	1168
J. GROSSET			
1.	Introduction	1168	
2.	Available Antibiotics	1168	
3.	Treatment of Leprosy before Multidrug Therapy		1172
4.	Treatment of Leprosy by Multidrug Therapy	1172	
5.	Current Research in Chemotherapy of Leprosy	1176	
47	Primycin	/	1179
A. BRYSKIER			
1.	Introduction	1179	
2.	Chemical Structure	1179	
3.	Physicochemical Properties	1179	

- 4. Toxicology 1180
- 5. Antibacterial Activity 1180
- 6. Pharmacokinetics 1180

48 Benzonaphthyridones / 1181

A. BRYSKIER

- 1. RP 60556 1181
- 2. RP 203246 1182

49 Agents against Methicillin-Resistant *Staphylococcus aureus* / 1183

ANDRÉ BRYSKIER

- 1. Introduction 1183
- 2. Glycopeptides 1185
- 3. Lipoglycopeptides 1186
- 4. Peptides 1188
- 5. Lipopeptides 1189
- 6. Natural Products of Plant and Marine Origin 1193
- 7. Miscellaneous Compounds 1195
- 8. β -Lactam Antibiotics 1212
- 9. Topical Antistaphylococcal Compounds 1223
- 10. Cyclines 1225
- 11. Macrolides/Ketolides 1225
- 12. Lincosamides 1225
- 13. Fluoroquinolones 1227
- 14. Oxazolidinones 1227
- 15. Deformylase Inhibitors 1227
- 16. Aminopeptidase Inhibitors 1230

50 Mutilins / 1239

A. BRYSKIER

- 1. Structure 1239
- 2. Antibacterial Activity 1239
- 3. Mode of Action 1239
- 4. Mechanism of Resistance 1239
- 5. TDM 85530 1240
- 6. SB 247386 1240

51 In Pursuit of New Antibiotics / 1242

ANDRÉ BRYSKIER

- 1. Introduction 1242
- 2. Future Research 1245
- 3. State of Progress of Research 1246
- 4. Conclusion 1256

52 Systemic Antifungal Agents / 1260

R. GRILLOT AND B. LEBEAU

- 1. Introduction 1260
- 2. Antifungal Antibiotics 1260
- 3. Chemical Antifungals 1270
- 4. Conclusions and Prospects 1285

53 Antifungal Targets and Research into Antifungal Agents / 1288

A. BRYSKIER

- 1. Introduction 1288
- 2. Targets of Antifungal Agents 1289
- 3. Miscellaneous Antifungal Agents 1314

4. Other Potential Sites 1318
5. Resistance Mechanisms 1318

54 Drug Interactions during Anti-Infective Treatments / 1320

O. PETITJEAN, P. NICOLAS, M. TOD, C. PADOIN, AND A. JACOLOT

1. Mechanistic and Methodological Approach 1320
2. Interaction and Drug Absorption 1320
3. Interactions Relating to the Distribution Phase 1325
4. Interactions Relating to the Elimination Phase 1330
5. Study of Clinical Interaction Profiles 1340
6. Prospects 1342
7. Evaluation of Potential Drug-Drug Interactions 1343

55 Antibiotic Treatments and the Intestinal Ecosystem / 1353

A. ANDREMONT

1. Why This Chapter? 1353
2. Composition of the Colonic Flora 1353
3. Specificity and Stability 1353
4. Dominant and Subdominant Flora 1353
5. Infections Due to Bacteria of the Intestinal Flora 1354
6. Resident, Transient, and Pathogenic Flora 1354
7. Resistance to Colonization, Barrier Effects, and Microbial Antagonism 1354
8. Methods of Studying the Effect of Antibiotics on Colonization Resistance 1354
9. Effect of Antibiotics on the Resident Flora and Decontamination 1355
10. Risks of Decontamination 1355
11. Conclusion 1355

56 Interaction between Antimicrobial Agents and the Oropharyngeal and Intestinal Normal Microflora / 1357

ÅSA SULLIVAN, CHARLOTTA EDLUND, AND CARL ERIK NORD

1. Background 1357
2. The Normal Oropharyngeal Microflora 1357
3. The Normal Intestinal Microflora 1357
4. Performance of Studies on the Interaction between Antimicrobial Agents and the Normal Microflora 1358
5. Impact of Penicillins on the Human Microflora 1359
6. Impact of Cephalosporins on the Human Microflora 1359
7. Impact of Monobactams, Carbapenems, and Glycopeptides on the Human Microflora 1361
8. Impact of Macrolides, Ketolides, Lincosamides, and Streptogramins on the Human Microflora 1362
9. Impact of Tetracyclines, Aminoglycosides, Nitrofurantoin, Oxazolidinone, Nitroimidazoles, and Folic Acid Antagonists on the Human Microflora 1363
10. Impact of Quinolones on the Human Microflora 1364
11. Conclusions 1366

57 Clinical Quality Assurance and the International Development of New Anti-Infective Agents / 1371

J. M. HUSSON, C. LIM, AND A. BRYSKIER

1. Introduction 1371
2. QA of Clinical Trials on Medicinal Products 1371

3. Problems Posed by the Clinical Evaluation of AIA 1375
4. Current State of Acceptance of Clinical Trials Abroad for the International
Registration of an AIA 1376
5. Conclusions 1376

Index 1379